Trials / Completed
CompletedNCT01705847
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-9820 | GS-9820 tablets containing 200 mg of GS-9820 administered orally |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2012-10-12
- Last updated
- 2016-05-17
Locations
4 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01705847. Inclusion in this directory is not an endorsement.